Page last updated: 2024-11-06

prednisolone and Pneumococcal Infections

prednisolone has been researched along with Pneumococcal Infections in 12 studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.

Research Excerpts

ExcerptRelevanceReference
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both."7.73Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006)
" About two months before this admission the patient was diagnosed as Henoch-Schönlein purpura nephritis who was treated with 40 mg/day of prednisolone(PSL)."3.74[Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy]. ( Iwasaki, S; Nagayama, Y; Yamaguchi, H; Yoshimura, A, 2007)
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both."3.73Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006)
"Bacterial keratitis results in corneal scarring and subsequent visual impairment."1.39Improvement in corneal scarring following bacterial keratitis. ( Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M, 2013)
"In rabbit models of untreated Pseudomonas keratitis and pneumococcal keratitis, topical 1% prednisolone phosphate, 0."1.28Topical anti-inflammatory agents in an animal model of microbial keratitis. ( Gritz, DC; Kwitko, S; Lee, TY; McDonnell, PJ, 1990)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19905 (41.67)18.7374
1990's2 (16.67)18.2507
2000's2 (16.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hafiji, J1
Bhogal, B1
Rytina, E1
Burrows, NP1
McClintic, SM1
Srinivasan, M2
Mascarenhas, J1
Greninger, DA1
Acharya, NR2
Lietman, TM2
Keenan, JD1
Ray, KJ1
Prajna, L1
Geetha, M1
Karpagam, R1
Glidden, D1
Oldenburg, CE1
Sun, CQ1
McLeod, SD1
SCHEIBNER, M1
MITCHELL, JH1
Kapetanovic, MC1
Saxne, T1
Sjöholm, A1
Truedsson, L1
Jönsson, G1
Geborek, P1
Nagayama, Y1
Iwasaki, S1
Yamaguchi, H1
Yoshimura, A1
Isenberg, DA1
Lipkin, DP1
Mowbray, JF1
Fisher, C1
Davies, R1
Wilcox, LD1
De Rose, G1
Cooke, D1
Bates, AK1
Kirkness, CM1
Ficker, LA1
Steele, AD1
Rice, NS1
Gritz, DC1
Lee, TY1
Kwitko, S1
McDonnell, PJ1
Kishimoto, M1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Steroids for Corneal Ulcers Trial[NCT00324168]Phase 4500 participants (Actual)Interventional2006-09-30Completed
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.[NCT03762824]Phase 4300 participants (Actual)Interventional2016-06-14Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Best Hard Contact Lens Corrected Visual Acuity Measured in logMAR, Correcting for Best Spectacle Corrected Visual Acuity at Enrollment

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment

InterventionlogMAR (Mean)
Steroid0.42
Placebo0.41

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 12 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 12 months from enrollment

InterventionlogMAR (Mean)
Steroid2.90
Placebo2.87

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment

InterventionlogMAR (Mean)
Steroid0.48
Placebo0.49

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR Using MIC (Minimum Inhibitory Concentration) to Moxifloxacin as a Covariate

Best spectacle-corrected visual acuity (BSCVA) for this outcome is measured in logMAR (logarithm of the Minimum Angle of Resolution) in which smaller values indicate better visual acuity. Minimum inhibitory concentration (MIC) to moxifloxacin was measured by E test and a log2-transformation of MIC was used in all analyses. In this analysis we add MIC to the model examining BSCVA at 3 months. (NCT00324168)
Timeframe: 3 months after enrollment

InterventionlogMAR (Mean)
Steroid0.50
Placebo0.46

Infiltrate/Scar Size, Correcting for Infiltrate/Scar Size at Enrollment

(NCT00324168)
Timeframe: 3 months from enrollment

Interventionmm (Mean)
Steroid3.07
Placebo3.02

Ocular Perforations

(NCT00324168)
Timeframe: At the time of perforation

Interventionparticipants (Number)
Steroid7
Placebo8

Time to Resolution of Epithelial Defect

This outcome measured time from enrollment to resolution of the epithelial defect in days for up to 21 days. For three weeks patients were examined every 3 days for size of epithelial defect until the defect was gone. (NCT00324168)
Timeframe: From enrollment up to 21 days

Interventiondays (Mean)
Steroid9.77
Placebo9.43

Subgroup Analysis of Best Spectacle-corrected Visual Acuity (BSCVA) by Categories of Infiltrate Depth

BSCVA measured in logMAR will be examined by categories infiltrate depth (categorized by depth percentage) by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months from enrollment

,
InterventionlogMAR (Mean)
>0-33%>33%-67%>67%-100%
Placebo0.260.470.86
Steroid0.350.520.80

Subgroup Analysis Predicting 3 Month Best Spectacle-corrected Visual Acuity (BSCVA) by Causative Organism

BSCVA measured in logMAR will be estimated by causative organism (either Nocardia spp, Streptococcus pneumoniae, Moraxella spp, or Pseudomonas aeruginosa). BSCVA will be examined for each causative organism by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months after enrollment

,
InterventionlogMAR (Mean)
Nocardia sppStreptococcus pneumoniaeMoraxella sppPseudomonas aeruginosa
Placebo0.360.520.260.45
Steroid0.540.490.460.53

Subgroup Analysis Predicting 3 Month Best Spectacle-corrected Visual Acuity (BSCVA) by Visual Acuity Group

Best spectacle-corrected visual acuity (BSCVA) for this subgroup analysis was measured in logMAR and then categorized by equivalent Snellen fractions (NCT00324168)
Timeframe: 3 months from enrollment

,
InterventionlogMAR (Mean)
<20/4020/40 to 20/800Counting fingers (CF) or worse
Placebo-0.020.381.15
Steroid0.060.361.00

Subgroup Analysis Predicting Best Spectacle-corrected Visual Acuity (BSCVA) as Stratified by Categories of Infiltrate/Scar Size

Best-spectacle visual acuity (BSCVA) at 3 months from enrollment is stratified by categories of infiltrate/scar size and examined by treatment arm (NCT00324168)
Timeframe: 3 months from enrollment

,
InterventionlogMAR (Mean)
0-1.90 mm1.91-2.70 mm2.71-4.06 mm4.07-8.90 mm
Placebo0.190.290.530.96
Steroid0.180.390.530.85

Trials

1 trial available for prednisolone and Pneumococcal Infections

ArticleYear
Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis.
    JAMA ophthalmology, 2013, Volume: 131, Issue:3

    Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Corneal Ulcer; Double-Blind Method; Drug Resi

2013

Other Studies

11 other studies available for prednisolone and Pneumococcal Infections

ArticleYear
Bullous pemphigoid in infancy developing after the first vaccination.
    Clinical and experimental dermatology, 2010, Volume: 35, Issue:8

    Topics: Diphtheria; Glucocorticoids; Haemophilus Infections; Heptavalent Pneumococcal Conjugate Vaccine; Hum

2010
Improvement in corneal scarring following bacterial keratitis.
    Eye (London, England), 2013, Volume: 27, Issue:3

    Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinol

2013
[Intralumbar Solu-Dacortin treatment of severe pneumococcal meningitis].
    Wiener klinische Wochenschrift, 1961, Apr-14, Volume: 73

    Topics: Humans; Meningitis; Meningitis, Meningococcal; Meningitis, Pneumococcal; Pneumococcal Infections; Pr

1961
PNEUMOCOCCAL MENINGO-ENCEPHALITIS. AN UNUSUAL CASE.
    Postgraduate medical journal, 1964, Volume: 40

    Topics: Ataxia; Body Image; Chloramphenicol; Encephalitis; Humans; Meningitis; Meningitis, Pneumococcal; Men

1964
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Rheumatology (Oxford, England), 2006, Volume: 45, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo

2006
[Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy].
    Nihon Jinzo Gakkai shi, 2007, Volume: 49, Issue:4

    Topics: Adult; Endocarditis, Bacterial; Humans; IgA Vasculitis; Male; Nephritis; Penicillin G; Pneumococcal

2007
Fatal pneumococcal epiglottitis in lupus overlap syndrome.
    Clinical rheumatology, 1984, Volume: 3, Issue:4

    Topics: Adult; Epiglottitis; Female; Humans; Laryngitis; Lupus Erythematosus, Systemic; Myositis; Pneumococc

1984
Use of the dog spleen for studying effects of irradiation and chemotherapeutic agents, with suggested uses of other organs.
    Cancer, 1976, Volume: 38, Issue:1

    Topics: Animals; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Dogs; Fluorouracil; Leukocytes; Mech

1976
Microbial keratitis after penetrating keratoplasty.
    Eye (London, England), 1990, Volume: 4 ( Pt 1)

    Topics: Adult; Aged; Aged, 80 and over; Chloramphenicol; Female; Graft Rejection; Humans; Keratitis; Keratit

1990
Topical anti-inflammatory agents in an animal model of microbial keratitis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1990, Volume: 108, Issue:7

    Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Flurbiprofen; Ke

1990
[Study on carbohydrate and insulin metabolism in experimental pneumococcal infections].
    Nihon Naibunpi Gakkai zasshi, 1965, Oct-20, Volume: 41, Issue:7

    Topics: Animals; Blood Protein Electrophoresis; Blood Proteins; Carbohydrate Metabolism; Diabetes Mellitus,

1965